Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

10,871 total articles

Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting

Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting

Taysha Gene Therapies announced new preclinical data demonstrating that their TSHA-102 gene therapy, based on self-complementary AAV9 delivering a miniaturized MECP2 transgene, achieves approximately 30-fold higher MeCP2 protein expression compared to a single-stranded AAV9 construct in neuronal models. These results validate the design of TSHA-102…

Lexeo Therapeutics Announces Multiple Presentations at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Lexeo Therapeutics Announces Multiple Presentations at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Lexeo Therapeutics announced multiple presentations at the 29th ASGCT Annual Meeting featuring new data on its cardiac gene therapy pipeline, including TNNI3 cardiomyopathy and Friedreich ataxia treatments, as well as advances in AAV manufacturing technology. The presentations highlight the company's innovative approaches and ongoing clinical trial…

Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults

Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults

Crinetics Pharmaceuticals announced that the European Commission has approved PALSONIFY® (paltusotine) for the treatment of acromegaly in adults, representing the first once-daily oral therapy approved in the EU. This approval is based on robust clinical data from two pivotal Phase 3 trials demonstrating efficacy, safety, and symptom improvement. W…

Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting

Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting

Cabaletta Bio announced multiple presentations at the ASGCT 2026 Annual Meeting showcasing clinical, translational, and manufacturing data on rese-cel, their investigational CAR T cell therapy for autoimmune diseases. Highlights include early clinical data without preconditioning, automated manufacturing advances, and single-cell profiling across v…

Auddia Announces Closing of $12 Million Public Offering

Auddia Announces Closing of $12 Million Public Offering

Auddia Inc., a US-based technology company specializing in AI-driven audio identification and classification, announced the closing of its $12 million public offering. The offering included common stock and warrants, aiming to support the company's working capital and general corporate purposes as it advances its audio AI platform and music promoti…

First Bank Announces First Quarter 2026 Net Income of $7.6 Million

First Bank Announces First Quarter 2026 Net Income of $7.6 Million

First Bank reported first quarter 2026 net income of $7.6 million, down from $9.4 million in the prior year period, driven by elevated credit loss expenses primarily related to its small business portfolio. The bank experienced modest growth in loans and deposits and maintained a strong and stable net interest margin of 3.69%. Despite increased non…

Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting

Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting

Dyne Therapeutics announced upcoming presentation of new preclinical data demonstrating its FORCE platform's ability to cross the blood-brain barrier and effectively knockdown MAPT RNA in the central nervous system of nonhuman primates and mice. This breakthrough highlights the platform's potential applications beyond neuromuscular diseases into ne…

Voyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer’s Disease

Voyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer’s Disease

Voyager Therapeutics announced eight presentations at ASGCT 2026 including a late-breaking oral presentation highlighting the safety and pharmacology of VY1706, its IV-delivered tau-silencing gene therapy targeting Alzheimer's disease. The company plans to submit an IND in Q2 2026 and initiate first-in-human dosing in the second half of 2026. Addit…

Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences

Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences

Editas Medicine announced upcoming presentations of new preclinical data for EDIT-401, their lead in vivo CRISPR gene editing candidate, demonstrating its potential as a transformative treatment for hyperlipidemia and related cardiovascular diseases. These presentations will occur across multiple prestigious scientific conferences in May 2026, high…

Montauk Renewables Schedules First Quarter 2026 Conference Call for Thursday, May 7, 2026, at 8:30 a.m. ET

Montauk Renewables Schedules First Quarter 2026 Conference Call for Thursday, May 7, 2026, at 8:30 a.m. ET

Montauk Renewables, a NASDAQ-listed renewable energy company, announced its first quarter 2026 earnings conference call to be held on May 7, 2026. The company specializes in converting biogas into renewable natural gas and renewable electricity, operating multiple projects across several U.S. states. Financial results will be released prior to the …

Hillman Reports First Quarter 2026 Results

Hillman Reports First Quarter 2026 Results

Hillman Solutions Corp. reported a 3.0% increase in net sales to $370.1 million in Q1 2026 but recorded a net loss of $4.7 million. The company completed acquisitions of Campbell Chain & Fittings and Delaney Hardware, expanding its Industrial MRO and Pro Distribution presence. It raised its full-year 2026 net sales guidance while maintaining Adjust…

XCharge Files 2025 Annual Report on Form 20-F

XCharge Files 2025 Annual Report on Form 20-F

XCharge, a Nasdaq-listed company specializing in electric vehicle charging and energy storage solutions, announced the filing of its annual report on Form 20-F for the fiscal year ending December 31, 2025. The report is accessible on the SEC and company websites, with hard copies available for shareholders upon request.

Sana Biotechnology Announces Oral Presentation Highlighting Preclinical Data from in vivo CAR T SG293 at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting

Sana Biotechnology Announces Oral Presentation Highlighting Preclinical Data from in vivo CAR T SG293 at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting

Sana Biotechnology announced that its preclinical data on SG293, a novel in vivo CAR T cell therapy using proprietary fusogen technology, will be presented orally at the ASGCT 2026 Annual Meeting. SG293 targets CD8+ T cells to generate CD19-directed CAR T cells with precision, aiming to treat both B-cell cancers and autoimmune diseases while minimi…

Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting

Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting

Cellectis announced new research on its TALE-based epigenetic editing approach showcased at the ASGCT annual meeting. This method achieves over 90% sustained gene knock-down in two key genes without creating DNA breaks or permanent sequence change, offering a potentially safer genome editing alternative. The platform expands Cellectis' gene editing…

Charlton Aria Acquisition Corporation Announces Extension of the Deadline for an Initial Business Combination

Charlton Aria Acquisition Corporation Announces Extension of the Deadline for an Initial Business Combination

Charlton Aria Acquisition Corporation, a Cayman Islands exempted blank check company listed on Nasdaq, announced that its Sponsor has deposited $850,000 into the trust account, granting an extension until July 25, 2026 to complete its initial business combination. This marks the utilization of the Company's option to extend the deadline by three mo…

TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting

TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting

TScan Therapeutics announced an upcoming poster presentation at the ASGCT 29th Annual Meeting featuring their novel CD45-targeted TCR-T cell therapies aimed at eliminating residual disease and preventing relapse post allogeneic hematopoietic cell transplantation in cancer patients. The data will be publicly available post-presentation, highlighting…

Millicom (Tigo) strengthens its position in Colombia following the successful acquisition of the government stake in Coltel

Millicom (Tigo) strengthens its position in Colombia following the successful acquisition of the government stake in Coltel

Millicom International Cellular S.A. (NASDAQ: TIGO) has acquired the remaining 32.5% government stake in Colombia Telecomunicaciones S.A. (Coltel), finalizing its consolidation of the company. This acquisition strengthens Millicom's market position in Colombia, providing increased scale and investment capacity to accelerate nationwide 5G rollout an…